Cargando…

Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer

Pancreatic cancer is characterized by constitutive activation of the mitogen-activated protein kinase (MAPK) pathway. Mutations of KRAS or BRAF and epigenetic abrogation of DUSP6 contribute synergistically to the constitutive activation of MAPK. Active MAPK induces the expression of a variety of gen...

Descripción completa

Detalles Bibliográficos
Autor principal: Furukawa, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316689/
https://www.ncbi.nlm.nih.gov/pubmed/25699241
http://dx.doi.org/10.3389/fonc.2015.00023
_version_ 1782355601395810304
author Furukawa, Toru
author_facet Furukawa, Toru
author_sort Furukawa, Toru
collection PubMed
description Pancreatic cancer is characterized by constitutive activation of the mitogen-activated protein kinase (MAPK) pathway. Mutations of KRAS or BRAF and epigenetic abrogation of DUSP6 contribute synergistically to the constitutive activation of MAPK. Active MAPK induces the expression of a variety of genes that are thought to play roles in malignant phenotypes of pancreatic cancer. By blocking the functions of such induced genes, it is possible to attenuate the malignant phenotypes. The development of drugs targeting genes downstream of MAPK may provide a novel therapeutic option for pancreatic cancer.
format Online
Article
Text
id pubmed-4316689
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-43166892015-02-19 Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer Furukawa, Toru Front Oncol Oncology Pancreatic cancer is characterized by constitutive activation of the mitogen-activated protein kinase (MAPK) pathway. Mutations of KRAS or BRAF and epigenetic abrogation of DUSP6 contribute synergistically to the constitutive activation of MAPK. Active MAPK induces the expression of a variety of genes that are thought to play roles in malignant phenotypes of pancreatic cancer. By blocking the functions of such induced genes, it is possible to attenuate the malignant phenotypes. The development of drugs targeting genes downstream of MAPK may provide a novel therapeutic option for pancreatic cancer. Frontiers Media S.A. 2015-02-04 /pmc/articles/PMC4316689/ /pubmed/25699241 http://dx.doi.org/10.3389/fonc.2015.00023 Text en Copyright © 2015 Furukawa. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Furukawa, Toru
Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer
title Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer
title_full Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer
title_fullStr Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer
title_full_unstemmed Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer
title_short Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer
title_sort impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316689/
https://www.ncbi.nlm.nih.gov/pubmed/25699241
http://dx.doi.org/10.3389/fonc.2015.00023
work_keys_str_mv AT furukawatoru impactsofactivationofthemitogenactivatedproteinkinasepathwayinpancreaticcancer